YY 1201

Drug Profile

YY 1201

Alternative Names: YY-1201

Latest Information Update: 18 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yooyoung Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Osteoarthritis

Most Recent Events

  • 01 Nov 2016 Yoo Young Pharmaceutical withdraws a phase I/II trial in Osteoarthritis prior to enrollment in South Korea (Intra-articular) (NCT02554552)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top